[Sinovac Biotech Ltd. 8,650,000 Common Shares We are offering 8,650,000 common shares through this prospectus supplement and the accompanying prospectus. Our common shares are listed on the NASDAQ Global Market under the symbol "SVA." The last reported sale price of our common shares on January 19, 2010 was $7.49 per share. Investing in our common shares involves a high degree]
[TABLE OF CONTENTS ABOUT THIS PROSPECTUS 1 WHERE YOU CAN FIND MORE INFORMATION ABOUT US 2 INCORPORATION OF DOCUMENTS BY REFERENCE 2 4 OUR COMPANY 5 RISK FACTORS 8 USE OF PROCEEDS 9]
[TABLE OF CONTENTS ABOUT THIS PROSPECTUS 1 WHERE YOU CAN FIND MORE INFORMATION ABOUT US 2 INCORPORATION OF DOCUMENTS BY REFERENCE 2 4 OUR COMPANY 5 RISK FACTORS 8 USE OF PROCEEDS 9]
[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]
[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]
[Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).] [01 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).] [01 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[Sinovac Reports Unaudited Third Quarter 2009 Financial Results - Conference call scheduled Monday, November 16, 2009 at 9:00 a.m. ET - BEIJING, Nov. 15 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2009. Financial Highlights · Sales for the] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[Sinovac Reports Unaudited Third Quarter 2009 Financial Results - Conference call scheduled Monday, November 16, 2009 at 9:00 a.m. ET - BEIJING, Nov. 15 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2009. Financial Highlights · Sales for the] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
[Law Debenture Corporate Services Inc. Copies to: st David T. Zhang, Esq. Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement. o ý o o o o CALCULATION OF REGISTRATION FEE] [[Letterhead of Rhudd & Associates] November 18, 2009 Sinovac Biotech Ltd. No.39 Shangdi Xi Road, Haidian District, Beijing 100085 Peoples Republic of China Dear Sirs, Sinovac Biotech Ltd. (the Company) For the purposes of giving this opinion, we have examined and relied upon copies of the following draft documents: (i) the Registration Statement; and (ii) the prospectus (the Prospectus) contained] [November 18, 2009 Sinovac Biotech Ltd. No.39 Shangdi Xi Road Haidian District, Beijing 100085 Peoples Republic of China Ladies and Gentlemen: Company Securities Registration Statement We have acted as special U.S. counsel to Sinovac Biotech Ltd., a limited liability corporation incorporated in Antigua, West Indies (the The facts, as we understand them, and upon which with your permission we] [November 18, 2009 Sinovac Biotech Ltd. No.39 Shangdi Xi Road, Haidian District, Beijing 100085 Peoples Republic of China Dear Sirs, Sinovac Biotech Ltd. (the Company) For the purposes of giving this opinion, we have examined and relied upon copies of the following draft documents: (i) the Registration Statement; and (ii) the prospectus (the Prospectus) contained in the Registration Statement. We] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Vancouver, Canada, November 18, 2009 Chartered Accountants]
